US chokehold pushes China chip self-sufficiency up the agenda
CPA’s Take : China is planning to spend over $1 trillion on catching up to the US in technology, especially chipmaking. The US must make
Public Company Corporate Tax Under the TCJA and Sales Factor Apportionment
In this article, published in Tax Notes Federal on Sept 21, 2020, CPA Chief Economist Jeff Ferry and CPA Board Member Bill Parks analyze the
Sugar Substitute Stevia Made With Forced Labor In China?
By Kenneth Rapoza, CPA Industry Analyst Is the sugar substitute stevia being harvested and produced through forced labor in China? Homeland thinks so. And Customs
Peter Navarro: Only Economic Nationalism Will Win the Day Against China
By Kenneth Rapoza, CPA Industry Analyst Peter Navarro spoke with the Hudson Institute’s Michael Pillsbury and said economic nationalism is the only way to protect
Congress Needs to Reestablish the Office of Technology Assessment
By Michael Stumo In 2019, a House resolution established a bipartisan “Select Committee on the Modernization of Congress” that sought to make Congress more efficient
U.S. Corporations Still Avoiding Corporate Taxes
David Morse is tax policy director at the Coalition for a Prosperous America Education Fund. Follow him on Twitter @CentristinIdaho. There was a lot of
Book shows how to put the ‘tough’ in ‘tough on China’
CPA’s Take: Roger Simmermaker has written multiple books on buying American and trade policy since 1996, and has been a CPA member since 2017. Both presidential
CPA Testimony on Economic Modeling of Trade Agreements
On Oct. 6th, CPA testified at a hearing of the US International Trade Commission on trade agreements. We focused on the failure of economic models
Modeling the Effect of the Market Access Charge on Exchange Rates, Interest Rates and the US Economy
This Working Paper examines the impact of the proposed Market Access Charge (MAC) on international capital inflows into the US economy and the domestic US
The U.S. needs to support American-made medicines
CPA’s Take: CivicaRX CEO Martin VanTrieste explains why it is essential, and achievable to reshore pharmaceutical production to the US. Two years ago, a group
